ORIOLA.HE Oriola
- Market cap
- EUR 146M
- P/E
- -
- P/B
- 1.56x
- ROE
- -1.9%
- Dividend yield
- 8.70%
- Fundamental score
- 2.0/5
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ORIOLA.HE undervalued?
Graham numberThe Graham number of Oriola cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oriola fundamental analysis
8 of 21 checks passedROE 0/2
Low return on equity (-1.9%), below 10%.
ROA 0/1
Return on assets (-0.2%) is below the industry median (-0.2%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-33.3%) is below the industry median (-33.3%).
Revenue Growth 1/2
Revenue grew 7.4% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (32.7%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 2/2
Cash covers 2.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.6x) is below the industry median (1.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 2/2
Dividend yield (8.7%) is in the top 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Oriola stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oriola
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs a…
Full company profileOriola financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oriola annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.59B | 1.53B | 1.55B | 1.72B | 1.80B | 1.45B | 1.54B | 1.49B | 1.68B | 1.91B | 206M |
| Gross Profit | 340M | 354M | 346M | 357M | 362M | 187M | 186M | 38.8M | 161M | 67.9M | 57.5M |
| Operating Income | 64.0M | 158M | 151M | 28.7M | 33.5M | 10.1M | 120M | 13.5M | 13.5M | 7.30M | 7.33M |
| EBITDA | 83.7M | 65.2M | 48.6M | 57.1M | 62.1M | 30.3M | 39.3M | 30.0M | -700K | 19.3M | 20.3M |
| Net Income | 42.8M | 26.3M | 10.8M | 8.00M | 11.3M | 11.3M | -2.40M | -20.7M | -20.1M | -27.2M | -1.73M |
| EPS | 0.24 | 0.14 | 0.06 | 0.04 | 0.06 | 0.06 | -0.01 | -0.11 | -0.11 | -0.15 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 925M | 922M | 928M | 1.03B | 1.17B | 1.09B | 961M | 935M | 876M | 946M | 772M |
| Total Liabilities | 720M | 725M | 746M | 873M | 996M | 876M | 735M | 763M | 742M | 845M | 680M |
| Shareholders' Equity | 205M | 198M | 182M | 157M | 170M | 217M | 226M | 171M | 133M | 101M | 91.8M |
| Cash & Short-term Investments | 60.8M | 17.0M | 65.8M | 70.8M | 168M | 109M | 161M | 138M | 114M | 152M | 109M |
| Total Debt | 112M | 128M | 117M | 177M | 278M | 210M | 125M | 118M | 76.1M | 70.0M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 40.1M | 23.7M | 103M | 84.4M | 58.3M | 40.0M | 77.9M | 9.60M | 38.7M | 60.0M | -38.5M |
| Capital Expenditure | 35.8M | 40.2M | 20.8M | 21.2M | 27.1M | 23.4M | 8.50M | 3.50M | 2.80M | 3.30M | 11.3M |
| Free Cash Flow | 4.30M | -16.5M | 82.0M | 63.2M | 31.2M | 16.6M | 69.4M | 6.10M | 35.9M | 56.7M | -49.9M |
| Ratios | |||||||||||
| ROE | 20.9% | 13.3% | 6.0% | 5.1% | 6.7% | 5.2% | -1.1% | -12.1% | -15.1% | -27.0% | -1.9% |
| ROA | 4.6% | 2.9% | 1.2% | 0.8% | 1.0% | 1.0% | -0.2% | -2.2% | -2.3% | -2.9% | -0.2% |
| Net Profit Margin | 2.7% | 1.7% | 0.7% | 0.5% | 0.6% | 0.8% | -0.2% | -1.4% | -1.2% | -1.4% | -0.8% |
| Debt to Equity | 0.54x | 0.65x | 0.65x | 1.13x | 1.64x | 0.97x | 0.55x | 0.69x | 0.57x | 0.69x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Oriola dividends
- Dividend yield
- 8.70%
- Forward dividend
- 0.03 EUR
- Payout ratio
- -
- Ex-dividend date
- Mar 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 12.7M | 0.07 | - |
| 2024 | EUR 12.7M | 0.07 | - |
| 2023 | EUR 10.9M | 0.06 | - |
| 2022 | EUR 7.30M | 0.04 | - |
| 2021 | EUR 5.40M | 0.03 | 47.8% |
| 2020 | 16.3M | 0.09 | 144.2% |
| 2019 | 16.3M | 0.09 | 203.8% |
| 2018 | 16.3M | 0.09 | 150.9% |
| 2017 | 25.4M | 0.14 | 96.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Oriola
- Insiders 32.74%
- Institutions 12.72%
- Public & others 54.55%
- Shares outstanding 184M
- Free float 138M
Oriola company profile
- Company name
- Oriola
- Ticker
- ORIOLA.HE
- ISIN
- FI0009014351
- Exchange
- Helsinki Exchange
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- Employees
- 796
- Fiscal year end
- December
- Address
- Orionintie 5, Espoo, Finland, 02200
- Phone
- 358 1042 999
- Website
- oriola.com
About Oriola
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products. In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, real world evidence, sales support, medical translation, pharmacovigilance and medical information, and patient support services. Further, the company provides advisory services. It serves pharmaceutical companies, pharmacies, veterinarians, hospitals, healthcare providers, special stores, retailers, and e-commerce companies. The company was founded in 1907 and is headquartered in Espoo, Finland.
Oriola management
10- Ms. Katarina Gabrielson M.Sc.President & CEO · born 1969
- Mr. Mats Danielsson M.Sc.EconChief Financial Officer · born 1969
- Ms. Tua Stenius-ÖrnhjelmManager of Investor Relations & Sustainability · born 1975
- Mr. Petter Sandstrom L.L.M.General Counsel & Secretary to the Board · born 1976
- Mr. Mikael Wegmüller M.Sc. (Econ.)Vice President of Communications & Sustainability · born 1966
- Mr. Stig Tornell B.Sc (Econ.)Executive VP of Sales · born 1967
- Ms. Maria Lundell M.A.Chief People Officer · born 1966
- Mr. Mikael Nurmi M.Sc.Chief Digital Officer · born 1967
- Ms. Katja Lundell M.Sc.Executive Vice President of Advisory Services · born 1974
- Ms. Satu Nylén M.Sc.Executive Vice President of Services & Products · born 1965